12/22/2025
Ionis Pharmaceuticals has shared a letter to the Angelman syndrome community on the ION582 clinical development program. The letter covers progress on the Phase 1/2 HALOS and Phase 3 REVEAL trials, as well as the recently announced CHAMPION trial to explore ION582 in additional genotypes.
Read the letter: https://bit.ly/48WCeNK